Date: 2016-05-10
Type of information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: Pfizer (USA - NY)
Product: PF-06671008
Action
mechanism: bispecific antibody. PF-06671008 is a dual-affinity re-targeting (DART®) bispecific molecule against P-cadherin and CD3.
Disease: advanced solid tumors
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC. (NCT02659631)
Latest
news: * On May 10, 2016, MacroGenics announced that its collaboration partner, Pfizer has advanced a bispecific antibody therapeutic candidate generated by MacroGenics' Dual-Affinity Re-Targeting, or DART®, platform. Pfizer recently dosed a first patient in the Phase 1 clinical study of PF-06671008, which targets P-cadherin and CD3. Increased levels of the protein P-cadherin have been reported in various tumors, including breast, ovarian, endometrial, colorectal and pancreatic cancers, and is correlated with poor survival of patients. The commencement of the Phase 1 study triggers a $2 million milestone payment to MacroGenics under the companies' October 2010 agreement. PF-06671008 is the first partner-developed DART molecule to enter clinical development and represents the sixth DART molecule in clinical testing. At present, MacroGenics' clinical pipeline includes multiple DART candidates for the treatment of cancer and one DART candidate for the treatment of autoimmune disorders.
